Journal of Alzheimers Disease & Parkinsonism
Open Access

Mini Review

Soluble Neuregulin-1 as a Diagnostic Biomarker for Alzheimer's Disease

¹Department of Bio and Fermentation Convergence, College of Natural Sciences, Kookmin University, 77 Jeongneung-Ro, Seongbuk-Gu, Seoul, South Korea

²Department of Neurosurgery, College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center,Seoul, 156-707, South Korea

*Corresponding Author:

Sang Hyung Lee
Department of Neurosurgery, College of Medicine
Seoul National University, SMG-SNU Boramae Medical Center
Seoul, South Korea 156-707
Tel: +82- 2-870-2302
E-mail: nslee@snu.ac.kr

Received date September 01, 2016; Accepted date October 10, 2016; Published date October 17, 2016

Citation: Liew H, Lee SH (2016) Soluble Neuregulin-1 as a Diagnostic Biomarker for Alzheimer’s Disease. J Alzheimers Dis Parkinsonism 6:271. doi: 10.4172/2161-0460.1000271

Copyright: © 2016 Liew H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Diagnosis using a biomarker is a faster and cheaper than brain imaging. Diagnostic biomarkers are chosen based on the characteristics of the disease, specificity, sensitivity, and stability during all disease stages. For this reason, previous candidates with insoluble form in a pathophysiological stage are not useful as biomarkers for the early stage of a neurodegenerative disease. In this study, we explored the possibility of using soluble proteins in cerebrospinal fluid, blood, or other peripheral materials as diagnostic biomarkers, in particular, the availability of soluble neuregulin-1 in blood.

Keywords